Note 11. Related Party Transactions

Pursuant to a Contribution and Assumption Agreement entered into on March 31, 2014 between Infusion and IBI, Infusion received assets of approximately $1,014,000, assumed $11,000,000 of obligations, and recognized a capital contribution of approximately $10,181,000 after all amounts owed by Infusion to IBI were extinguished. IBI was Infusion's Parent prior to the reverse merger and is currently ASTV's largest shareholder with 85.2% ownership of outstanding common stock. A summary of the assets contributed and liabilities assumed follows:


Cash	$	31,161
Note receivable		711,220
Interest receivable		259,584
Property and equipment, net		6,660
Deposits		5,392
Total IBI assets contributed to Infusion		1,014,017

Note payable		(11,000,000	)
Total liabilities assumed		(11,000,000	)
Net liabilities assumed by Infusion		(9,985,983	)
Forgiveness of debt		20,167,184
Contribution to capital	$	10,181,201

Shadron Stastney, an officer and member of our board of directors, is a member in and chief operating officer of Vicis Capital, LLC, the investment advisor to Vicis Capital Master Fund. Vicis Capital Master Fund is the holder of our 6% Senior Secured Debenture. At June 30, 2014, the outstanding balance of the debenture is $11,211,562. See note 12.

Ronco is indebted to CD3, its sole shareholder, for approximately $3 million (Note 12). The indebtedness is in the form of a promissory note. In addition, Ronco has an outstanding receivable from CD3 in the amount of $358,954 and contains no payment or interest terms.

Included within the assets IBI contributed to Infusion, there is an 18% bearing note receivable due from CD3 with a past due outstanding principal amount of approximately $711,000 with accrued interest receivable of approximately $259,000. As of June 30, 2014, the outstanding principal amount of approximately $711,000 and accrued interest receivable of approximately $292,000 is included in the note receivable related party caption of the Condensed Consolidated Balance Sheet.